Biomarin Pharmaceutical (BMRN) Free Cash Flow (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Free Cash Flow came in at $199.7 million in Q1 2026, up 26.71% YoY from $157.6 million in Q1 2025, and up 238.97% on a QoQ basis from $58.9 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Free Cash Flow (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Free Cash Flow data on file, last reported at $199.7 million in Q1 2026.
- Quarterly Free Cash Flow rose 26.71% year-over-year to $199.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $767.1 million (up 22.89% YoY) and the FY2025 annual result came in at $725.0 million, up 48.73% from the prior year.
- Free Cash Flow climbed to $199.7 million in Q1 2026, from $58.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $319.9 million in Q3 2025 to a low of -$126.3 million in Q4 2022.
- A 5-year average of $93.8 million and a median of $94.2 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 2629.3% — and 2025, when it surged 655.38%.
- Tracing BMRN's Free Cash Flow over 5 years: stood at -$126.3 million in 2022, then surged by 150.75% to $64.1 million in 2023, then jumped by 159.09% to $166.1 million in 2024, then tumbled by 64.53% to $58.9 million in 2025, then soared by 238.97% to $199.7 million in 2026.
- The last three Free Cash Flow figures came in at $199.7 million (Q1 2026), $58.9 million (Q4 2025), and $319.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 139.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139.29 Mn |
| Jun 30, 2026 | 139.29 Mn |
| Mar 31, 2026 | 199.73 Mn |
| Mar 31, 2026 | 199.73 Mn |
| Dec 31, 2025 | 58.92 Mn |
| Dec 31, 2025 | 58.92 Mn |
| Sep 30, 2025 | 319.87 Mn |
| Sep 30, 2025 | 319.87 Mn |
| Jun 30, 2025 | 188.53 Mn |
| Jun 30, 2025 | 188.53 Mn |
| Mar 31, 2025 | 157.63 Mn |
| Mar 31, 2025 | 157.63 Mn |
| Dec 31, 2024 | 166.10 Mn |
| Dec 31, 2024 | 166.10 Mn |
| Sep 30, 2024 | 203.02 Mn |
| Sep 30, 2024 | 203.02 Mn |
| Jun 30, 2024 | 97.44 Mn |
| Jun 30, 2024 | 97.44 Mn |
| Mar 31, 2024 | 20.87 Mn |
| Mar 31, 2024 | 20.87 Mn |